StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.96+0.01 (+1.44%)

Close on Nov 17, 2026Market cap $26.64MP/E –Yield –

Inmune Bio operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Inmune Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$14.96M. For fiscal 2025 it was -$22.58M. The highest annual figure on record is -$761.83K in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.58M–
FY2024Dec 31, 2024-$33.36M–
FY2023Dec 31, 2023-$11.98M–
FY2022Dec 31, 2022-$22.69M–
FY2021Dec 31, 2021-$28.50M–
FY2020Dec 31, 2020-$8.94M–
FY2019Dec 31, 2019-$5.38M–
FY2018Dec 31, 2018-$2.06M–
FY2017Dec 31, 2017-$761.83K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.18M–
Q1 FY2026Mar 31, 2026-$3.40M–
Q4 FY2025Dec 31, 2025-$2.94M–
Q3 FY2025Sep 30, 2025-$5.44M–
Q2 FY2025Jun 30, 2025-$7.38M–
Q1 FY2025Mar 31, 2025-$6.82M–
Q4 FY2024Dec 31, 2024-$11.01M–
Q3 FY2024Sep 30, 2024-$6.99M–
Q2 FY2024Jun 30, 2024-$7.89M–
Q1 FY2024Mar 31, 2024-$7.48M–
Q4 FY2023Dec 31, 2023-$3.40M–
Q3 FY2023Sep 30, 2023-$4.26M–
Q2 FY2023Jun 30, 2023-$3.17M–
Q1 FY2023Mar 31, 2023-$1.14M–
Q4 FY2022Dec 31, 2022-$5.70M–
Q3 FY2022Sep 30, 2022-$3.37M–
Q2 FY2022Jun 30, 2022-$4.76M–
Q1 FY2022Mar 31, 2022-$8.87M–
Q4 FY2021Dec 31, 2021-$9.78M–
Q3 FY2021Sep 30, 2021-$7.92M–
Q2 FY2021Jun 30, 2021-$5.71M–
Q1 FY2021Mar 31, 2021-$5.09M–
Q4 FY2020Dec 31, 2020-$2.39M–
Q3 FY2020Sep 30, 2020-$3.70M–
Q2 FY2020Jun 30, 2020-$1.82M–
Q1 FY2020Mar 31, 2020-$1.04M–
Q4 FY2019Dec 31, 2019-$433.37K–
Q3 FY2019Sep 30, 2019-$1.95M–
Q2 FY2019Jun 30, 2019-$1.62M–
Q1 FY2019Mar 31, 2019-$1.39M–
Q4 FY2018Dec 31, 2018-$462.38K–
Q3 FY2018Sep 30, 2018-$449.93K–
Q2 FY2018Jun 30, 2018-$817.85K–
Q1 FY2018Mar 31, 2018-$328.84K–

More Inmune Bio figures

See a number that looks wrong?